Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03100344 · ClinicalTrials.gov registry record · Phase 2
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
A Phase 2 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 2
- Development phase
- 226
- Enrollment target
NCT03100344 is a Phase 2 study that has completed, run by Galderma R&D. The registered enrollment target is 226 participants.
The verdict
NCT03100344, a Phase 2 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 226 participants
- Enrollment target
Study Summary
Assess the efficacy of several subcutaneous doses of nemolizumab in moderate-to-severe atopic dermatitis (AD) subjects with severe pruritus receiving TCS, who were not adequately controlled with topical treatments.
Interventions
- DRUG Placebo
- DRUG Nemolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2017-06-14 |
| Est. Completion | 2018-09-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03100344
The ClinicalTrials.gov registry entry for NCT03100344 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 226 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03100344 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03100344 about?
NCT03100344 is a clinical study titled "Dose-ranging Study of Nemolizumab in Atopic Dermatitis". Assess the efficacy of several subcutaneous doses of nemolizumab in moderate-to-severe atopic dermatitis (AD) subjects with severe pruritus receiving TCS, who were not adequately controlled with topical treatments.
What is the current status of trial NCT03100344?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 226 participants. The study started on 2017-06-14. Estimated completion is 2018-09-21.
What interventions are being tested in trial NCT03100344?
The interventions under investigation include: Placebo (DRUG), Nemolizumab (DRUG).
Who is sponsoring clinical trial NCT03100344?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.